On March 28, 2023, the U.S. Food and Drug Administration (FDA) released an Immediate National Strategy to Increase the Resiliency of the U.S. Infant Formula Market. On the same day, the agency’s response to the recent infant formula safety and supply crisis was called into question during a hearing with the U.S. House of Representatives Subcommittee on Health Care and Financial Services Hearing.
The strategy and hearing follow a months-long infant formula shortage beginning in February 2022, sparked by insanitary conditions at one of the nation’s largest infant formula facilities, leading to a significant voluntary recall and production shutdown.